See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
Phase 2 study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19
Phase 2 study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Population pharmacokinetic/ pharmacodynamic analyses of cefiderocol for paediatric patients
Population pharmacokinetic/ pharmacodynamic analyses of cefiderocol for paediatric patients
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model